Malignant peripheral nerve sheath tumours (MPNSTs) are aggressive soft tissue tumours that occur either sporadically or in patients with neurofibromatosis type 1. The malignant transformation of the benign neurofibroma to MPNST is incompletely understood at the molecular level. We have determined the gene expression signature for benign and malignant PNSTs and found that the major trend in malignant transformation from neurofibroma to MPNST consists of the loss of expression of a large number of genes, rather than widespread increase in gene expression. Relatively few genes are expressed at higher levels in MPNSTs and these include genes involved in cell proliferation and genes implicated in tumour metastasis. In addition, a gene expression signature indicating p53 inactivation is seen in the majority of MPNSTs. Subsequent microRNA profiling of benign and malignant PNSTs indicated a relative down-regulation of miR-34a in most MPNSTs compared to neurofibromas. In vitro studies using the cell lines MPNST-14 (NF1 mutant) and MPNST-724 (from a non-NF1 individual) show that exogenous expression of p53 or miR-34a promotes apoptotic cell death. In addition, exogenous expression of p53 in MPNST cells induces miR-34a and other miRNAs. Our data show that p53 inactivation and subsequent loss of expression of miR-34a may significantly contribute to the MPNST development. Collectively, our findings suggest that deregulation of miRNAs has a potential role in the malignant transformation process in peripheral nerve sheath tumours.
Introduction
Malignant peripheral nerve sheath tumours (MPNSTs) are aggressive sarcomas that are associated with a 5-year survival rate of ∼40% [1] . Approximately half of MPNSTs occur as sporadic cases; the remainder arise in patients with the autosomal dominant genetic disorder neurofibromatosis type 1 (NF1). NF1 is caused by inactivating mutations in the NF1 gene and affects 1 : 3000 live births. It is associated with a significant risk of developing malignancies, especially MPNSTs, which occur in NF1 patients with an incidence of ∼10% [2] [3] [4] . In NF1 patients, MPNSTs most often develop from preexisting neurofibromas. Screening for malignant transformation in NF1 patients is difficult, due to the large number and diverse anatomical sites of neurofibromas that occur in these patients. As a result, most MPNSTs are identified at a late clinical stage [1, 2] . The development of MPNSTs from neurofibromas is a complex process and a number of studies have described different molecular findings in these lesions. Both NF1-associated and sporadic MPNSTs are characterized by loss of NF1 expression [5] that leads to increased RAS signalling and increased cell proliferation [6] . Molecular events such as DNA amplification with gain of expression of TOP2A and EGFR [7, 8] , and inactivation of CDKN2A and p53 [9] [10] [11] have been implicated in malignant transformation towards MPNSTs. Yang et al [12] , using a mouse model of NF1, demonstrated that for neurofibroma formation, Nf1 haploinsufficiency is required in the nonneoplastic cells of the tumour micro-environment and also implicated mast cells as critical mediators of neurofibroma initiation. Earlier studies have shown differences in the gene expression patterns between neurofibromas and MPNSTs, and between dermal and plexiform neurofibromas [13, 14] . However, NF1-associated and sporadic MPNSTs could not be distinguished by gene expression profiling [15] . Miller et al [16] demonstrated down-regulation of Schwann cell differentiation markers in MPNST and showed that reduction of TWIST1 expression inhibited chemotaxis.
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Regulation of gene expression can occur through post-transcriptional modification by microRNAs (miRNAs). These small non-coding RNAs are 18-22 nucleotides in length [17] and have been implicated in apoptosis, proliferation, and differentiation [18] . Using murine and human cell lines, it was recently shown that the tumour suppressor function of the transcription factor p53 involves up-regulation of a network of miRNAs that includes miR-34a [19] . Expression of miR-34a in turn regulates a large number of genes associated with the cell cycle and proliferation [20] . In order to understand the potential role of miRNAs in the malignant transformation process, we analysed the global mRNA and miRNA expression profiles of peripheral nerve sheath tumours using gene microarrays and used in vitro approaches to study the possible role of miR-34a in malignant transformation in MPNSTs.
Materials and methods
The reader is referred to the Supporting information, Supplementary Materials and methods section for details.
Tumour samples
Ninety-seven fresh frozen tumour samples [20 MPNSTs, 37 neurofibromas, 27 Schwannomas, and 13 synovial sarcomas (SSs)] were obtained and centrally reviewed (CDMF). Clinicopathological features of the tumour samples are shown in Table 1 
Array analysis
The Stanford cDNA microarrays used in the study contain approximately 42 000 spots, representing about 28 000 genes or expressed sequence tags (http://www. microarray.org/). A total of 5229 genes showed significant variation in expression and were used for further analysis. Unsupervised hybrid hierarchical clustering, SAM analysis, and gene set enrichment analysis were performed as described in the Supporting information, Supplementary Materials and methods section.
The Stanford microRNA microarrays used in the study contained 482 known and predicted human miRNAs and 28 control probes (Ambion, Austin, TX, USA) spotted in duplicates (see the Supporting information, Supplementary Materials and methods section for details).
Cell culture and transfection, plasmid constructs, cell viability assays, and qRT-PCR Two MPNST cell lines (JAF) were used for in vitro studies. MPNST-14 cells were established from a young NF1 male; the p53 is WT in exons 4-10. MPNST-724 cells were established from a non-NF1 primary tumour with p53 mutation (codon 254 deletion) and deletion of other p53 allele (see the Supporting information, Supplementary Materials and methods section, Supplementary Table 2 , and Supplementary Figure 1 for details).
The complete raw data for mRNA and miRNA expression profiles will be made available through the Stanford Microarray Database (http://smd.stanford. edu/). Supplementary tables can be better viewed as Excel files. Percentage is based on the background genes for each group.
Gene expression profiles of peripheral nerve sheath tumours
histologically a low-grade nerve sheath tumour. Six neurofibromas clustered with MPNSTs in branch B; however, clustering of MPNSTs and neurofibromas was not associated with known NF1 status of the tumour and there were no histological or molecular features detected that distinguished these six cases from the other neurofibromas. The major distinction between neurofibromas and MPNSTs is the lower level of expression of a large number of genes in MPNSTs rather than a widespread increase in expression levels. The 5229 differentially expressed genes separated into four major transcriptional gene groups. The gene ontology terms associated with each transcriptional gene group are given in Table 2 and the complete gene list is given in the Supporting information, Supplementary Table 3 .
SAM analysis of gene expression in MPNST versus neurofibroma
SAM analysis was performed to identify genes that are differentially expressed between MPNST samples and benign peripheral nerve sheath tumours. CRABP1, BEX1, CPA3, DLK1, HIST1H2BD, CYTL1, LOC388152, and IGFBP2 were the eight genes that were highly expressed in all MPNSTs relative to the benign nerve sheath tumours (FDR 1%). Large numbers of genes (∼2200) were expressed at lower levels in MPNSTs, compared with benign peripheral nerve sheath tumours. The genes with low levels of expression in MPNSTs included L1CAM, CDH1, ERBB3, MAL, SOX10, CRYAB, CD44, S100B, and PMP22 ( Figure 2 ). These genes have significant SAM negative scores. Genes such as L1CAM, CRYAB, SOX10, and S100B were previously reported to be downregulated in MPNSTs [16] , and MPNSTs often show only focal reactivity for S100B in immunohistochemistry. The complete list of genes differentially expressed in MPNSTs relative to neurofibromas is given in the Supporting information, Supplementary Table 4 .
MPNSTs are known to display a variety of histological appearances and the diagnosis of MPNST is among the most difficult in sarcoma histopathology. In an effort to discover more genes that are differentially expressed between the malignant and benign nerve sheath tumours, we considered the 15 MPNSTs in branch B as a group distinct from the five cases that clustered with the benign peripheral nerve sheath tumours in branch A. We compared the gene expression levels of these 15 'core' MPNSTs with 'core' neurofibromas (neurofibromas clustered in branch A of Figure 1 ). This SAM analysis identified over 300 genes that are significantly up-regulated in the 'core' MPNSTs (FDR 1%). Several genes such as CRABP1, CRABP2, IGF2, TPX2, ADNP, PBK, PTK7, FOXM1, TOP2A, TWIST1, and NEK2 ( Figure 2 ) were up-regulated in this group and these have been previously implicated in various cancers [22] . The complete lists of high ranking positive and negative genes in 'core MPNSTs' and neurofibromas are listed in the Supporting information, Supplementary Tables 5 and 6 , respectively. NF1  CRABP1  BEX1  CPA3  DLK1  IGFBP2  L1CAM  CDH1  ERBB3  MAL  MAL  SOX10  CRYAB  PMP22  CRABP2  IGF2  TPX2  ADNP  PBK  PTK7  FOXM1  TOP2A  TWISTNB  TWIST1  NEK2   MN1  GAS1  CCNB2  CDC2  CDC6  CDC7  CDC45L  PBK  PTN  TTK  BUB1  MCM6  MCM4  MCM6  BUB1  PLK1  CCNB2  TOP2A  FOXM1  MKI67  MCAM  CDH2  L1CAM  CDH1  VCAM1  CD44  CD58  ALCAM  ITGA2  ITGA6  ITGA9  ITGAV  TWIST1  UBE2C  HMMR  THBS1  THBS2  BMPR2  TGFBR2  STAT1  WNT5A  CDH1  BCL2  PTCH  CDKN1B  FOS  MYC  JUN  PTK7  PLK1  NEK2  FGFR1  FGFR2  AURKB  MAPK7  EPHA4  EPHB6  EGFR  MELK  ROS1  MAP3K10  CAMK4   SSX1  SSX4  ZIC2  RIPK4  CA14  TLE1  MSX1  MSX2  RUNX2  POSTN  TFPI  LUM  ETV1  LPHN2  DNMT3A LATS2 MEST POLE PTTG1 S100B SNAI2 -MPNST  STT3990 -MPNST  STT3920 -MPNST  STT4628 -MPNST  STT4541 -MPNST  STT4532 -MPNST  STT4630 -MPNST  STT3922 -MPNST  STT3992 -MPNST  STT108a -MPNST  STT3989 -MPNST  STT3927 -MPNST  STT1999 -MPNST  STT3916 -MPNST  STT4737 -MPNST  STT4740 -MPNST  STT4734 -MPNST  STT2252 -MPNST  STT1825 -MPNST  STT3991 -MPNST  STT1989 -SS  STT4635 -SS  STT4636 -SS  STT3705 -SS  STT3217 -SS  STT862 -SS  STT1774 -SS  STT1739 -SS  STT638 -SS  STT4638 -SS  STT4637 -SS  STT4366 -SS  STT3994 - Overview of several expression patterns of groups of genes described in the text involved in cell cycle regulation, cell adhesion, metastasis, and other gene networks. Some genes that are associated with more than one gene grouping appear more than once
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STT4003 -Schwannoma STT861 -Schwannoma STT4140 -Schwannoma STT4171 -Schwannoma STT981 -Schwannoma STT4010 -Schwannoma STT4125 -Schwannoma STT4008 -Schwannoma STT3054 -Schwannoma STT4270 -Schwannoma STT4274 -Schwannoma STT524 -Schwannoma STT3998 -Schwannoma STT3999 -Schwannoma STT3997 -Schwannoma STT4000 -Schwannoma STT723 -Schwannoma STT3227 -Schwannoma STT2109 -schwannoma STT3845 -Schwannoma STT513 -Schwannoma STT3062 -neurofibroma STT4736 -neurofibroma STT4012 -neurofibroma STT4733 -neurofibroma STT4498 -neurofibroma STT4488 -neurofibroma STT4528 -neurofibroma STT4536 -neurofibroma STT4546 -neurofibroma STT4527 -neurofibroma STT4544 -neurofibroma STT4473 -neurofibroma STT4531 -neurofibroma STT4545 -neurofibroma STT4499 -neurofibroma STT4538 -neurofibroma STT4537 -neurofibroma STT4497 -neurofibroma STT4474 -neurofibroma STT4543 -neurofibroma STT4534 -neurofibroma STT4529 -neurofibroma STT4494 -neurofibroma STT4011 -neurofibroma STT4100 -neurofibroma STT4496 -neurofibroma STT4627
Expression profiles in MPNST associated with known function
MPNSTs showed lower levels of expression of the NF1 gene, with a fold change of 0.237 compared with neurofibromas. While numerically most genes were expressed at lower levels in the majority of MPNSTs compared with benign nerve sheath tumours, a significant number of genes involved in cell division, cell proliferation, migration, and malignant transformation were expressed at higher levels in MPNSTs (Figure 2 ). 
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Loss of cell adhesion
Several cell adhesion genes, such as MCAM, CDH2, L1CAM, VCAM1, CD44, CD58, ALCAM, and ITGAs (integrins), were expressed at lower levels in MPNSTs relative to neurofibromas. E-cadherin (CDH1 ) was down-regulated in both neurofibromas and MPNSTs compared with Schwannomas and SSs, whereas CDH2, a neuronal cell adhesion molecule, was downregulated in MPNSTs but expressed at higher levels in neurofibromas.
Metastatic signature
TWIST1, UBE2C, and HMMR are implicated in malignant progression and metastasis [24, 25] . Compared with the benign PNSTs, most MPNSTs and SSs showed elevated expression of TWIST1 and UBEC2, while increased expression of HMMR was more frequently seen in MPNSTs alone. In MPNSTs, there was a significant down-regulation of thrombospondin (THBS1 and THBS2, inhibitors of angiogenesis). The repression of thrombospondin leads directly to angiogenesis and tumour formation in mammary epithelial cells and kidney cells [26] .
Signalling pathways affected in MPNST
Gene set enrichment analysis [27] was used to identify signalling pathways affected in MPNSTs. By comparing 'core' MPNSTs and 'core' neurofibromas, several signalling pathways were identified that appear to be associated with malignant transformation. Genes associated with signalling pathways [such as the extracellular matrix (ECM) pathway], cancer-related genes involved in immune function, and genes involved in cell death were significantly downregulated in MPNSTs. The list of affected pathways ranked based on their enrichment score is given in Table 3 . As an example, the data for the ECM pathway are shown in the Supporting information, Supplementary Figure 2 . The TGFB pathway-related genes, such as TGFBR2 and STAT1, are down-regulated in MPNSTs ( Figure 2 ). We noticed relative low expression of several tumour suppressor genes (BMPR2, TGFBR2, CDH1, WNT5A, ITGAs, NF1, BCL2, PTCH, and CDKN1B ) in MPNSTs. In addition, MPNSTs were characterized by increased expression of several kinase family genes, as shown in Figure 2 . Although EGFR was highly expressed in a subset of MPNST cases (Figure 2 ), the SAM analysis did not rank EGFR as one of the high ranking genes in MPNSTs, as this gene was also highly expressed in a subset of neurofibromas. Figure 3A) . By gene array analysis, only one of 21 Schwannomas showed high levels of EGFR expression. This was the only Schwannoma that clustered with the malignant cases in branch B of Figure 1 . Of the 68 MPNST cases represented on the tissue microarray, 44 were NF1-associated and 24 were sporadic cases. EGFR staining showed no significant correlation with NF1 status (66% of NF1-associated MPNSTs and 71% of sporadic MPNSTs showed EGFR staining) ( Figure 3B ). Representative examples of EGFR staining on peripheral nerve sheath tumours and synovial sarcoma are shown in Figures 3C-3H . 
Tissue microarray validation of EGFR expression
Loss of p53 function
Loss of p53 function has been associated with increased cell proliferation. We analysed the expression patterns of the 38 genes that represent the 'inactivated p53-associated proliferation signature' [28] in the neurofibromas and MPNSTs. The analysis revealed that several of these 'p53 inactivation'-associated genes such as TOP2A, TTK, CDC2, HMMR, PTTG1, and UBE2C were up-regulated in MPNSTs (Figure 4 ). Though most MPNSTs included in the analysis showed the signature for p53 inactivation, four MPNST tumour cases (STT4734, STT4737, STT4541, and STT3920) did not show the signature for p53 inactivation. Of these four cases, two (cases STT3920 and STT4541) clustered with the benign tumours in the unsupervised clustering shown in Figure 1 . Only a single neurofibroma (case STT4538) showed the expression signature for p53 inactivation. Conversely, genes that were down-regulated due to inactivation of p53 (PDE5A, TAGLN, CUL4B, and UGCG) showed elevated expression in the majority of neurofibromas compared with MPNSTs ( Figure 4 ).
MicroRNA expression signature in PNSTs
miRNA expression profiling was performed for 482 known and predicted human miRNAs on 23 peripheral nerve sheath tumours (six MPNSTs, 11 neurofibromas, and six Schwannomas). The six MPNSTs had also been used for mRNA profiling (Figure 1 ). Distinct miRNA expression profiles clearly distinguished MPNSTs from the benign tumours in unsupervised clustering using the 64 miRNAs that met the filtering criteria. Among the benign tumours, neurofibromas and Schwannomas clustered separately (Figure 5a ). Using significance analysis of microarrays (SAM) analysis, we identified the miRNAs that were differentially expressed in each peripheral nerve sheath tumour class. In comparison with benign tumours, five SFPQ  RBMX  TFRC  RRM2  TOP2A  MCM6  CENPF  MAD2L1  CCNB2  CDC2  TACC3  POLE  RFC3  SPAG5  UBE2C  GMNN  RFC4  KIF4A  TRIP13  ZWINT  CDKN3  BUB1B  CKS2  HMMR  CDC25C  BUB1  ITGB3BP  NEK2  PRIM1  TTK  PTTG1  CDKN1A  PDE5A  TAGLN  ACTA2  CUL4B  UGCG  COPZ2   STT4734-MPNST  STT4737-MPNST  STT4740-MPNST  STT3916-MPNST  STT1999-MPNST  STT3927-MPNST  STT3991-MPNST  STT1825-MPNST  STT2252-MPNST  STT3989-MPNST  STT4630-MPNST  STT108a-MPNST  STT3992-MPNST  STT3922-MPNST  STT1989-MPNST  STT4541-MPNST  STT3920-MPNST  STT4627-MPNST  STT3990-MPNST  STT4532- Thirty-eight of the 168 genes described by Milyavsky et al [28] to be differentially expressed after p53 inactivation were available for analysis in our study. The genes in the upper part of the figure are expressed at higher levels after p53 inactivation and show a higher level of expression in MPNST than in neurofibroma. The genes in the lower part of the figure (shown in blue) are a group of eight genes that are down-regulated due to p53 inactivation in the study of Milyavsky et al [28] and are expressed at low levels in MPNSTs. A few MPNST cases (four cases in total) did not show the p53 inactivation signature and are highlighted in blue; two of these (STT4541 and 3920) clustered with the benign PNSTs in branch A of Figure 1 miRNAs (miR-214, miR-377, miR409-3p, miR-487b, and miR-99b) were relatively up-regulated and miR-517, miR-34a, miR-29a, miR-30e-5p, and miR-27a were down-regulated in MPNSTs (FDR 1%). The gene expression profiling data showed the gene signature for p53 inactivation in the majority of MPNSTs as shown in Figure 4 . Since p53 is a transcription factor and miR-34a is one of the direct transcriptional targets of p53 [19] , we selected miR-34a for further functional characterization. As a confirmation of the miRNA array data, quantification of miR-34a along with nine other differentially expressed miRNAs by qRT-PCR in five neurofibroma and MPNST patients' tumour samples validated the microRNA array data (Figure 5b ).
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MPNST STT4100-neurofibroma STT3062-neurofibroma STT4496-neurofibroma STT4494-neurofibroma STT4011-neurofibroma STT4529-neurofibroma STT4538-neurofibroma STT4499-neurofibroma STT4545-neurofibroma STT4473-neurofibroma STT4546-neurofibroma STT4527-neurofibroma STT4544-neurofibroma STT4531-neurofibroma STT4474-neurofibroma STT4497-neurofibroma STT4537-neurofibroma STT4543-neurofibroma STT4528-neurofibroma STT4536-neurofibroma STT4736-neurofibroma STT4733-neurofibroma STT4488-neurofibroma STT4498-neurofibroma STT4012-neurofibroma
Down-regulation of miR-34a in MPNST is due to p53 inactivation
We determined the expression levels of ten known p53-induced miRNAs [29] including miR-34a, miR34b, miR-34c, miR-638, miR-373 * , miR-492, miR-126, miR-140, miR-491, and miR-296 in the MPNST cell lines. Comparison of the expression levels of these miRNAs in MPNST-14 and MPNST-724 cells with HEK-293 cells (p53 positive) shows that both of these MPNST cell lines have at least two to ten times lower levels of these p53-dependent miRNAs (Figure 5c ). Our mRNA and miRNA data analysis suggested that miR-34a transcript levels may depend on p53 activation in MPNSTs; to confirm this, we determined the transcript levels of miR-34a and other p53-dependent miRNAs by qRT-PCR after overexpressing wild-type p53 in both of the MPNST cell lines by transfection with wt-p53-GFP-containing plasmid. We found a significant increase in the levels of miR-34a and nine other p53-dependent miRNAs in these transfected cells (Figure 5d ), confirming that in MPNST, miR-34a expression is dependent on p53 activation status.
Ectopic expression of p53 or miR-34a promotes apoptotic cell death in MPNST cells
The MPNST-14 cell line is deficient in miR-34a expression and we hypothesized that exogenous expression of either p53 or its direct transcriptional target miR-34a in this cell line would induce apoptosis in these MPNST cells. To test this, we transfected MPNST-14 cells with miR-34a expression construct and subjected the transfected cells to live/dead assay (Figure 6a , ii). We noticed approximately 36.23% of cell mortality in MPNST-14 cells, which was similar to its transfection efficiency with the miR-34a construct (about 40%; Supporting information, Supplementary Figure 3) . Furthermore, the presence of transfected miRs was verified in these cells using qRT-PCR (Supporting information, Supplementary Figure 3b) . In contrast, transfection of MPNST-14 cells with scrambled sequence vectors showed only 5.19% dead cells. In addition, transfection with miR-34b and miR34c had little or no effect on cell survival, with 5.16% and 4.46% cell death, respectively.
We performed FACS analysis using transfected cells and could show that the dead cells contained fragmented DNA, a characteristic feature of apoptosis (Figure 6b) . We examined the effect of exogenous expression of wild-type p53 in MPNST-14 cells. Transfection of wild-type p53 resulted in 40% dead cells (Figure 6a, iv) , similar to that of miR-34a transfection. Transfection with empty vector controls yielded far fewer dead cells (2.73%).
The transfection efficiency of MPNST cells is only about 40%. In order to determine the actual percentage of dead cells amongst successfully transfected cells, miR-34a and p53-transfected cells were enriched by FACS based on GFP fluorescence. The transfectionenriched cell populations were next subjected to FACS analysis using PI staining. The miR-34a transfectionenriched population and p53 transfection-enriched population had over 90% dead cells (Supporting information, Supplementary Figure 4) .
Transfection experiments were also carried out with the second MPNST cell line, MPNST-724, a cell line derived from a non-NF1 individual (Supporting information, Supplementary Table 7) . With miR-34a transfection, the apoptotic response in MPNST-724 cells was 38.79%, similar to that seen in MPNST-14 (NF1 mutant) cells (36.23%). We also found a similar percentage of apoptosis (40.43%) with p53 transfection of MPNST-724 cells. Transfection with the scrambled sequences and empty vector controls had 5.11% and 2.19% dead cells, respectively (Figure 6c) . In order to understand the possible mechanism by which miR-34a induces apoptosis in these MPNST cells, we determined the levels of MYCN, E2F, and CDK4 in miR-34a transfected MPNST cells by qRT-PCR. These mRNA targets are known to be influenced by miR-34a [30, 31] . We found that expression of these mRNAs was decreased (by 38-40%) upon miR-34a transfection (Figure 6d ).
Discussion
Our gene microarray analysis identified expression signatures for the four classes of tumours (MPNST, neurofibroma, Schwannoma, and synovial sarcoma) included in the study. Unsupervised hybrid clustering separated the majority of the benign tumours from the malignant tumours. There were a few outliers in each class of tumour, which may reflect alterations of gene expression seen in different stages of tumour progression. For example, six of 26 neurofibroma cases clustered in the branch containing most of the MPNSTs. Though these neurofibroma cases show morphological features diagnostic of a typical neurofibroma, the possibility cannot be excluded that early pre-malignant disturbances at the molecular level have occurred in these cases and have resulted in a gene expression profile more similar to MPNSTs than to typical neurofibromas. For five of these six neurofibromas, the NF1 status was known and four were resected from NF1 patients. In contrast, of the 20 neurofibromas clustering on branch A, the NF1 status of 16 cases were known, eight of which were resected from NF1 patients. In our study, we were unable to distinguish NF1-associated and sporadic MPNSTs based on gene expression profiles. This finding is in agreement with previous studies [13, 15] . Compared with neurofibromas, the majority of the MPNSTs showed a decreased level of expression for a large number of genes. A possible explanation for this finding is that the majority of the 'group 1' genes that are down-regulated in MPNST are associated with nucleic acid-binding functions (Table 2) . This may explain the down-regulation of many genes downstream from these transcription factors. Alternatively, epigenetic changes, such as DNA methylation, can also affect gene expression levels. For example, DNMT3A (an effector of DNA methylation) and genes known to be affected by DNA methylation (such as CDH1, LATS2, IGF2, and MEST ) [32] are differentially expressed in peripheral nerve sheath tumours, suggesting a possible role for DNA hypermethylation. In addition, a recent study showed that PTEN is hypermethylated in 29% of MPNSTs [33] , and site-specific methylation involving transcription factor binding sites for AP2 and SP1 in the NF1 gene has been found in plexiform neurofibromas [34] .
A search for genes that are uniquely overexpressed in all the MPNSTs included in the study yielded only eight genes. This is consistent with the heterogeneous nature of MPNSTs, and this heterogeneity is also reflected in their variable histological appearance and their clustering pattern in our unsupervised cluster analysis. However, when analysing the 'core MPNSTs', those present in branch B of Figure 1 , high expression of genes that are involved in cell proliferation and that are implicated in the pathogenesis of other cancer types was found. Genes such as TOP2A and TWIST1, which have been previously implicated in the progression of MPNSTs [7, 16] , were also found to be overexpressed in our gene array analysis. Likewise, CRABP1 was one of the top five genes highly expressed in MPNSTs in our study. In a previous study, Henderson et al [35] noted that high expression of CRABP1 distinguished MPNSTs and SSs from other mesenchymal tumours. Loss of expression of genes such as E-cadherin and overexpression of the zinc-finger transcriptional repressor gene 'snail' (SNAI2 ) are associated with tumour invasion [36, 37] . This interactive mechanism of down-regulation of Ecadherin and up-regulation of SNAI2 was observed in most MPNSTs in our mRNA expression study.
Similar to earlier reports [13, 38] , our TMA analysis revealed elevated expression of EGFR in a subset of MPNSTs and neurofibromas. EGFR expression was not associated with the mutational status of NF1. Gene and TMA analyses showed no EGFR expression in any of the Schwannomas included in this study. Earlier studies have shown that EGFR is expressed in a subset of NF1-mutant Schwann cells and not in normal Schwann cells [39] . Furthermore, a majority of the synovial sarcomas stained for EGFR, which is in agreement with previous findings from our laboratory [21] .
Histological distinction between SS and MPNST often poses a diagnostic challenge. SAM analysis revealed SSX, ZIC2, RIPK4, CA14, and TLE1 to be the top-ranking genes that are expressed at higher levels in SSs compared with MPNSTs (Supporting information, Supplementary Table 8) . We have previously shown that an antibody against TLE1 is a useful diagnostic tool for SS [40] . One of the SS cases, STT3994, clustered with the MPNSTs (Figure 1 ). RT-PCR for the diagnostic t(X;18) showed an unusually small fusion product of 297 bp (the usual fusion product seen in other cases of SS is 585 bp). Sequencing identified a novel, previously unreported fusion of exon 8 SYT gene to exon 7 SSX1 (Supporting information, Supplementary Figure 5 ). Interestingly, this SS case had relatively lower levels of TLE1 expression compared with the other SS samples (Figure 1) .
Two noticeable miRNA-mRNA associations became apparent in our study. Firstly, miRNA expression analysis indentified miR-214 as the top overexpressed miRNA in MPNSTs. TWIST1, a master regulator of metastasis, has been shown in mouse neural cells to induce miR-214 expression [41] . It is notable that TWIST1 is highly expressed in the majority of MPNSTs and thus may be involved in miR-214 expression in MPNSTs as well.
Secondly, several miRNAs were down-regulated in MPNSTs compared with the benign nerve sheath tumours, including miR-34a. Initial studies on primary and tumour-derived cell lines have shown that p53 induces the expression of miR-34a [19, 29, 42] . Subsequent studies have demonstrated that miR-34a expression induces apoptosis in colon cancer and neuroblastomas [30, 43] ; however, no sarcoma samples were included in these studies. To understand better the mechanism of the association between p53 and miR-34a expression in MPNST, we used two MPNST cell lines: MPNST-14 and MPNST-724. Despite the presence of intact genomic loci for miR-34 family miRNAs (data not shown), both MPNST cell lines had lower levels of endogenous miR-34 levels compared with HEK-293 cells. Relative down-regulation of miR34a in these cell lines is consistent with the lower level of miRNA seen in MPNST tumour samples and with our observation that the majority of MPNSTs show a gene expression signature that is associated with p53 inactivation. Transfection of p53 in MPNST cells induced the expression of miR-34a and other p53-dependent miRNAs. In addition, exogenous expression of either p53 or miR-34a in the MPNST cell lines induced apoptosis-mediated cell death in over 90% of the transfected MPNST cells.
In the majority of MPNSTs, p53 is inactivated either by mutation or through other unknown mechanisms. In our study, miR-29a was significantly down-regulated in MPNSTs; miR-29 family miRs can activate p53 by blocking CDC42 and p85α, the negative regulators of p53 [44] . Furthermore, in our functional assay, only miR-34a showed apoptosis-mediated cell death in the MPNST cells, whereas miR-34b and miR-34c did not produce any significant effect in the transfected MPNST cell line. miR-34a and miR-34c have an identical seed sequence, an important determinant of mRNA target specificity [45] . However, a search in miRgen for consensus target prediction showed only a partial overlap in the targets for these two miRNAs (data not shown), indicating that other factors play a role in the determination of targets.
In the MPNST cell lines, MYCN, E2F3, and CDK4 transcript levels were down-regulated upon miR-34a transfection. MYCN oncogene mRNA is a known target of miR-34a, and MYC protein levels are reduced up to 80-95% upon miR-34a expression [31] . E2F family members are pro-apoptotic and miR-34a is known to mediate apoptosis by significantly reducing
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